Current Report · Items 1.01, 8.01, 9.01 · 8-K
Cel-Sci Corporation
CVMNYSE_AMERICANEQUITYCurrent
Entry into a Material Definitive Agreement · Other Events
Item 1.01 Entry into a Material Definitive Agreement. On August 27, 2025, CEL-SCI Corporation, a Colorado corporation (the “Company”), entered into a Placement Agency Agreement with ThinkEquity LLC (the “Placement Agent”) relating to the sale and issuance of 1,111,200 shares of the Company’s common stock, at an offering price of $9.00 per share (the “Shares”). The Offering closed on August 29, 2025.…
Filed Aug 29, 2025Accepted Aug 29, 2025, 1:15 PM EDTCIK 725363Accession 0001654954-25-010184
Company context
We are a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. We are currently focused on the development of the following product candidates and technologies with emphasis on Multikine:
Current securities
Historical securities (1)
Disclosure sections
Items 1.01, 8.01, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement.
On August 27, 2025, CEL-SCI Corporation, a Colorado corporation (the “Company”), entered into a Placement Agency Agreement with ThinkEquity LLC (the “Placement Agent”) relating to the sale and issuance of 1,111,200 shares of the Company’s common stock, at an offering price of $9.00 per share (the “Shares”).
The Offering closed on August 29, 2025. The gross proceeds from the Offering were approximately $10,000,800 before deducting Placement Agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering to fund the continued development of Multikine, for general corporate purposes, and working capital.
The securities were offered and sold by the Company pursuant to the Company’s effective registration statement on Form S-3 (Registration No. 333-288515) which was declared effective by the Securities Exchange and Commission (the “SEC”) on August 12, 2025, the base prospectus included therein, as amended and supplemented by the prospectus supplement dated August 27, 2025.
Pursuant to the terms of the Placement Agency Agreement, the Company agreed to pay the Placement Agent a cash fee equal to 7.0% of the gross proceeds of the Offering and to reimburse the Placement Agent for certain of its expenses (including fees and expenses of its legal counsel) in an aggregate amount up to $185,000. The Company further agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock or file any registration statement or prospectus, or any amendment or supplement thereto for a period of 30 days from the closing of this offering, subject to certain exceptions. Additionally, each of the directors and officers of the Company, pursuant to lock-up agreements, agreed not to sell or transfer any of the Company securities which they hold, subject to certain exceptions, for a period of 45 days from the closing of this offering.
The Placement Agency Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Placement Agent, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of the parties and termination provisions. The foregoing description of the Placement Agency Agreement is not complete and is qualified in its entirety by reference to the full text of the Placement Agency Agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.
This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Item 8.01Item 8.01 - Other Events
Item 8.01
Other Events.
On August 27, 2025, the Company issued a press release announcing the pricing of the Offering, which press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
On August 29, 2025, the Company issued a press release announcing the closing of the Offering. A copy of this press release is attached as Exhibit 99.2.
The information in this Item 8.01, including Exhibit 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Forward-Looking Statements
Certain of the statements made in this Current Report on Form 8-K are forward looking. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by the Company is contained under the caption “Risk Factors” in the Company’s prospectus supplement filed with the SEC on August 27, 2025 pursuant to Rule 424(b)(5) promulgated under the Securities Act, the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2024 filed with the SEC on January 13, 2025, and other filings made by the Company with the SEC, all of which can be obtained on the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Filed exhibits (2)
EX-99.1 (by filename) cvm_ex991.htmEX-99.1
4
cvm_ex991.htm
PRESS RELEASE
cvm_ex991.htm
EXHIBIT 99.1
NEWS RELEASE
8229 Boone Boulevard, Suite 802 COMPANY CONTACT:
Vienna, VA 22182. USA Gavin de Windt
Telephone (703) 506-9460 CEL-SCI Corporation
www.cel-sci.com (703) 506-9460
CEL-SCI ANNOUNCES PRICING OF $10 MILLION PUBLIC OFFERING
Vienna, Virginia - August 27, 2025 - CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 1,111,200 shares of its common stock. Each share of common stock is being sold at a public offering price of $9.00 per share. Total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, are expected to be approximately $10 million. The offering is expected to close on August 29, 2025, subject to satisfaction of customary closing conditions.
The Company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate purposes, and working capital.
ThinkEquity is acting as the sole placement agent for th…
Open exhibit ↗EX-99.2 (by filename) cvm_ex992.htmEX-99.2
5
cvm_ex992.htm
PRESS RELEASE
cvm_ex992.htm
EXHIBIT 99.2
NEWS RELEASE
8229 Boone Boulevard, Suite 802 COMPANY CONTACT:
────────────────────────────────────────────────────────────
Vienna, VA 22182. USA Gavin de Windt
Telephone (703) 506-9460 CEL-SCI Corporation
www.cel-sci.com (703) 506-9460
CEL-SCI ANNOUNCES CLOSING OF $10 MILLION PUBLIC OFFERING
Vienna, Virginia - August 29, 2025 - CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its offering of 1,111,200 shares of its common stock. Each share of common stock was sold at a public offering price of $9.00 per share. Total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, were approximately $10 million.
The Company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate purposes, and working capital.
ThinkEquity acted as the sole placement agent for the offering.
The securities were offered and sold pursuant to a shelf registration state…
Open exhibit ↗